| All the studies (n = 76) n (%) |
---|---|
Study design | |
 Retrospective cohort | 54 (71) |
 Prospective cohort | 21 (28) |
 Randomized controlled trial | 1 (1.3) |
Type of study time-to-event outcomea | |
 Cured | 9 (12) |
 Treatment complete | 27 (36) |
 Treatment failure | 16 (21) |
 Death | 72 (95) |
 Default | 37 (49) |
 Transfer out | 5 (6.6) |
Study size | |
 Median [IQR] | 492 [286–1330] |
 Minimum to Maximum | 56–182,890 |
Survival analyses objective | |
 Curve estimation | 2 (2.6) |
 Survival regression analyses | 16 (21) |
 Both | 58 (76) |
Involvement of statistician/epidemiologist | |
 Yes | 43 (57) |
 Not reported | 54 (71) |
Authors affiliationb | |
 Country of focus only | 21 (28) |
 Country of focus plus other African country | 5 (6.6) |
 Country of focus plus developed country | 55 (72) |
Publication Journal | |
 PLOS One | 22 (29) |
 International Journal of Tuberculosis and Lung Diseases (IJTLD) | 9 (12) |
 BMC Infectious Disease | 9 (12) |
 BMC Public Health | 4 (5.3) |
 Clinical Infectious Disease | 3 (3.9) |
 Othersc | 29 (38) |
Statistical software used | |
 SPSS | 15 (20) |
 SAS | 9 (12) |
 STATA | 40 (53) |
 R | 7 (9.2) |
 Not reported | 5 (6.6) |